Julie Winter supports Corporate Development at Kyverna Therapeutics. Prior to Kyverna she was V.P. Business Development at PaxVax, Inc., where she led major corporate transactions, culminating in the sale of PaxVax to Emergent Biosolutions in 2018 for $270 million. Since the sale of PaxVax, she has worked with a number of start-ups and public companies on corporate development, partnering and strategy, spanning products based on gene therapy and small molecule platforms among other areas, and therapeutic areas including oncology, immunology and CNS. Julie has also been working with a venture group on company ideation at the nexus between AI and therapeutics.
Prior to PaxVax, from 2012 to 2017 Julie was Director, Business Development at Ferrer International, where she was responsible for leading in-licensing efforts. She led a number of transactions, including licensing of Rapidscan, Kengrexal and Cleviprex. Julie has also worked in venture capital, serving as a junior partner at InterWest Partners, and a venture partner with Sofinnova Ventures in Europe, and brings an international perspective to her work.
Ms. Winter has served on corporate boards both in the U.S. and internationally, including Aerogen, Epicor, and ERA Biotech.
Julie earned a BA in Biology cum laude from Smith College and an MBA from Stanford University, where she also completed a PhD-level course in immunology.